REG - Oxford Cannabinoid - Directors’ Dealings

Oxford Cannabinoid Technologies HoldingsAnnouncement

26/02/2024 13:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240226:nRSZ4819Ea&default-theme=true

RNS Number : 4819E  Oxford Cannabinoid Tech.Holdings  26 February 2024

Oxford Cannabinoid Technologies Holdings plc

("OCT" or the "Company")

 

Directors' Dealings

 

Oxford Cannabinoid Technologies Holdings plc (LSE:OCTP), the biotech company
developing prescription cannabinoid medicines, announces that it has been
informed that Clarissa Sowemimo-Coker, the Chief Executive Officer of the
Company, and Julie Pomeroy, the Company's Non-Executive Chair, have today
purchased ordinary shares of £0.001 ("Ordinary Shares") in the Company.

 

 Director                 Total number of Ordinary Shares purchased  Price per Ordinary Share  Number of Ordinary Shares held following the purchase
 Clarissa Sowemimo-Coker  1,000,000                                  £0.0045                   2,500,000
 Julie Pomeroy            450,000                                    £0.004575                 650,000

 

Clarissa Sowemimo-Coker, Chief Executive Officer of OCT, said:

 

"Today marks further evidence of the management's support of OCT, following
our participation in a successful fundraise in January 2024 where we also
welcomed Cantheon Capital LLC as a cornerstone investor of the Company. Both I
and OCT's chair, Julie Pomeroy, have increased our personal shareholdings in
OCT, demonstrating our commitment to the business and our resolute belief in
the Company's future pipeline. I look forward to continuing to work with
colleagues to deliver further for our shareholders with the ultimate aim of
helping people living with debilitating conditions."

 

The PDMR forms are set out below.

 

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018).

The Directors of the Company take responsibility for this announcement.

 

Enquiries:

 

 Oxford Cannabinoid Technologies Holdings plc  +44 (0)20 3034 2820
 Clarissa Sowemimo-Coker (CEO)                 clarissa@oxcantech.com

 Cairn Financial Advisers LLP
 Emily Staples                                 +44 (0)20 7213 0897
 Jo Turner                                     +44 (0) 20 7213 0885

 Axis Capital Markets Limited
 Richard Hutchison                             +44 (0)20 3026 0320

 Acuitas Communications                        020 3745 0293 / 07799 767676
 Simon Nayyar                                  simon.nayyar@acuitascomms.com
 Arthur Dingemans                              arthur.dingemans@acuitascomms.com

 

About Oxford Cannabinoid Technologies Holdings Plc:

Oxford Cannabinoid Technologies Holdings plc ("OCT") is the holding company
of Oxford Cannabinoid Technologies Ltd and OCT Victoria Pty Ltd (together the
"Group"), a pharmaceutical Group developing prescription cannabinoid
medicines initially targeting the US$ multi-billion global pain market.

 

OCT currently has a portfolio of four drug development programmes. Its lead
compound, OCT461201, will initially target neuropathic and visceral pain
(including irritable bowel syndrome ("IBS") and chemotherapy induced
peripheral neuropathy ("CIPN"). The global market for CIPN alone is currently
forecast to reach US$1.17bn by 2028.

 

OCT's drug development pipeline comprises both natural and synthetic
compounds, and includes compounds targeting trigeminal neuralgia, a severe
type of face pain, and cannabinoid derivatives targeting pain and potentially
other therapeutic areas. Having established an exclusive licence agreement
with Canopy Growth Corporation for their entire pharmaceutical cannabinoid
derivative library, OCT now has a portfolio of almost five hundred derivatives
and intellectual property rights including fourteen patent families and
associated research data.

 

OCT has a clearly defined path to commercialisation, revenues and growth. The
Group is developing drug candidates through clinical trials to gain regulatory
approval (FDA/MHRA/EMA) that will enable medical professionals to prescribe
them with confidence. OCT's portfolio aims to balance risk, value and time to
market, whilst ensuring market exclusivity around all its key activities.

 

 

 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
 596/2014
 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name                                                         Clarissa Sowemimo-Coker
 2   Reason for notification

 a.  Position/Status                                              Chief Executive Officer
 b.  Initial notification/                                        Initial notification

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         Oxford Cannabinoid Technologies Holdings plc
 b.  LEI

                                                                  2138005SRWT4998BCE35

 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument

Identification Code                                         Ordinary shares of £0.001 each

                                                                  GB00BMVMRB86
 b.  Nature of the transaction                                    Acquisition of ordinary shares of £0.001 each
 c.  Price(s) and volume(s)
                                                                              Price(s)    Volume(s)
     £0.0045                                                                  1,000,000

 d.  Aggregated information                                       N/A - Single Transaction

     - Aggregated Volume

     - Price
 e.  Date of the transaction                                      26 February 2024
 f.  Place of the transaction                                     London, UK
 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
 596/2014
 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name                                                         Julie Pomeroy
 2   Reason for notification

 a.  Position/Status                                              Non-Executive Chair
 b.  Initial notification/                                        Initial notification

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         Oxford Cannabinoid Technologies Holdings plc
 b.  LEI

                                                                  2138005SRWT4998BCE35

 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument

Identification Code                                         Ordinary shares of £0.001 each

                                                                  GB00BMVMRB86
 b.  Nature of the transaction                                    Acquisition of ordinary shares of £0.001 each
 c.  Price(s) and volume(s)
                                                                              Price(s)    Volume(s)
     £0.004575                                                                450,000

 d.  Aggregated information                                       N/A - Single Transaction

     - Aggregated Volume

     - Price
 e.  Date of the transaction                                      26 February 2024
 f.  Place of the transaction                                     London, UK

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHGZGZZFVDGDZM